Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHIN-214 in advanced cirrhosis
NCT05490888Phase 1Recruiting
- Sponsor
- PharmaIN Corporation
- Start
- Jan 2022
- Primary completion
- May 2026
- Modality
- Peptides, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PHIN-214 in Liver cirrhosis (LC) (2 arms), sponsored by PharmaIN Corporation. Primary endpoints: Maximum Tolerated Dose / Optimal Beneficial Dose up to 6 weeks, Pharmacokinetics of PHIN-214 up to 6 weeks and 1 more. Started Jan 2022; status: recruiting.
02
Drugs
PHIN-214
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT05490888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490888.